MAPT and amyloidosis: This is because AI has the potential to overcome the diagnostic limitations of existing molecular biomarkers (such as amyloid plaque and tau in cerebrospinal fluid) and imaging methods (such as computed tomography (CT), MRI, amyloid PET imaging, and PETFDG imaging).